NKTX at a glance
Nkarta, Inc. (NKTX, SEC CIK 1787400) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 10, 2026 and Form 4 insider filings as recently as June 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Nkarta, Inc. (NKTX) reported revenue of $0 and a net loss of $104.1 million. Diluted EPS was -$1.41.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Nkarta, Inc. (NKTX) shares worth $57.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by HASTINGS PAUL J on June 18, 2026 of 1,776 shares at $2.71 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $57.6M · +1 vs prior quarter
- Latest 8-K
- Aug 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- No product revenue; no products approved for sale
- Significant losses since inception; continued losses expected for the foreseeable future
- Additional capital required, with potential dilution or operational restrictions
- Key near-term dependency: NKX019 clinical success and regulatory approval
- Major headwinds: clinical uncertainty, enrollment delays, manufacturing complexity, and competition
Risk Factors
- Newly triggered impairment risk: June 2026 manufacturing optimization and facility sublease rendered equipment unused, causing long-lived-asset impairment charges
- Most materially updated financial risk: net losses reached $68.2 million for six months ended June 30, 2026, with accumulated deficit of $716.5 million
- Regulatory risk: novel CAR NK autoimmune therapies lack FDA-approved precedents, potentially extending review and delaying commercialization
- Operational risk: halted enrollment in hematologic-malignancy trials after deprioritizing NKX019 and NKX101 programs
- Financing risk: $243.2 million in cash, restricted cash, equivalents and investments as of June 30, 2026, but pivotal trials require additional capital
AI summary of the NKTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release scheduled for August 10, 2026
Item EX-99.1: Item EX-99.1
- NKX019 enrollment continues across six autoimmune indications at 4 billion cells per dose, with 12 billion cells per three-dose cycle
- Outpatient dosing now underway at community sites, potentially improving trial access and supporting scalable treatment delivery
Item 5.07: Submission of Matters to a Vote of Security Holders
- Two Class III directors, Ali Behbahani and Zachary Scheiner, re-elected through the 2029 annual meeting
- Ernst & Young LLP appointment ratified for the year ending December 31, 2026, with 53,684,352 votes supporting
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 financial results announcement for quarter ended March 31, 2026
- Press release contains the substantive financial figures and management commentary
AI summaries of NKTX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NKTX
Don't miss the next NKTX filing
- Alerts as it files. A push when NKTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NKTX, by share count.
- Ask anything. An AI agent that reads every NKTX filing and answers with sources.
NKTX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| HASTINGS PAUL J | Sell | Jun 18, 2026 | 1,776 | $2.71 |
| Behbahani Ali | A | Jun 10, 2026 | 37,000 | - |
| PATTERSON LEONE D | A | Jun 10, 2026 | 37,000 | - |
| Scheiner Zachary | A | Jun 10, 2026 | 37,000 | - |
| Vratsanos George | A | Jun 10, 2026 | 37,000 | - |
| RA CAPITAL MANAGEMENT, L.P. | A | Jun 10, 2026 | 37,000 | - |
| Thedinga Angela | A | Jun 10, 2026 | 37,000 | - |
| George Simeon | A | Jun 10, 2026 | 37,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $0 |
| Operating Income | - | -$128.2M | -$122.0M |
| Net Income | -$117.5M | -$108.8M | -$104.1M |
| Balance Sheet | |||
| Total Assets | - | $501.2M | $404.2M |
| Equity | - | $408.0M | $312.3M |
| ROE | - | -26.7% | -33.3% |
| Per Share | |||
| EPS | $-2.40 | $-1.60 | $-1.41 |
| Cash Flow | |||
| Operating CF | -$86.2M | -$99.7M | -$88.7M |
| CapEx | $28.1M | $4.4M | $1.2M |
Source: XBRL data in Nkarta, Inc. (NKTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate NKTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $57.6M |
| Q1 2026 | 24 | $36.4M |
| Q4 2025 | 24 | $29.1M |
| Q3 2025 | 22 | $35.8M |
| Q2 2025 | 22 | $28.0M |
| Q1 2025 | 19 | $27.4M |
| Q4 2024 | 16 | $27.6M |
| Q3 2024 | 18 | $41.2M |
- BlackRock+1.79M (+40%)
- AQR Capital Management+458.5K (+77%)
- Citadel Advisors LLC+390.8K (+22%)
- Vanguard Capital Management LLC+215.0K (+11%)
- Millennium Management+178.0K (+122%)
- Renaissance Technologies LLC−554.7K (-32%)
- D.E. Shaw & Co−194.4K (-54%)
- Two Sigma Investments−174.1K (-9%)
- Morgan Stanley−49.3K (-16%)
- Northern Trust−45.7K (-11%)
- Blackstone Group+747.0K
- Raymond James Financial+10.9K
- Prudential Financial−62.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 170 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NKTX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Mar 26, 2026 | - | - | - |
| 8-K | Mar 25, 2026 | - | - | - |
| 10-K | Mar 25, 2026 | Dec 31, 2025 | - | |
| 4 | Jan 20, 2026 | - | - | |
| 4 | Jan 20, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - | |
| 10-Q | Nov 10, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 12, 2025 | Jun 30, 2025 | - | |
| 10-Q | May 14, 2025 | Mar 31, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
NKTX SEC filings: frequently asked questions
Which institutions hold NKTX stock?
As of June 30, 2026, the largest Nkarta, Inc. (NKTX) holders among the 13F filers tracked by SignalX were BlackRock ($17.8 million), Vanguard Capital Management LLC ($6.3 million), Citadel Advisors LLC ($6.2 million), Two Sigma Investments ($5.3 million), State Street Corp ($3.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NKTX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Nkarta, Inc. (NKTX) reported revenue of $0 and a net loss of $104.1 million. Diluted EPS was -$1.41. The figures come from the XBRL data in the 10-K.
What did NKTX report in its latest 8-K?
Nkarta, Inc. (NKTX) filed an 8-K on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
What are the latest NKTX SEC filings?
Nkarta, Inc. (NKTX) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 10, 2026 and a Form 4 insider filing on June 22, 2026.
What is NKTX's SEC CIK number?
Nkarta, Inc. (NKTX)'s SEC Central Index Key (CIK) is 1787400. EDGAR lists every NKTX filing under that number.
Ask anything about NKTX
The research agent reads NKTX's filings, financials, insider trades and 13F holders, then answers with sources.